Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 yearCitation formats

  • External authors:
  • Phoebe Rich
  • Kristian Reich
  • Frank O. Nestle
  • Richard K. Scher
  • Shu Li
  • Stephen Xu
  • Ming Chun Hsu
  • Cynthia Guzzo

Standard

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. / Rich, Phoebe; Griffiths, Christopher E M; Reich, Kristian; Nestle, Frank O.; Scher, Richard K.; Li, Shu; Xu, Stephen; Hsu, Ming Chun; Guzzo, Cynthia.

In: Journal of the American Academy of Dermatology, Vol. 58, No. 2, 02.2008, p. 224-231.

Research output: Contribution to journalArticlepeer-review

Harvard

Rich, P, Griffiths, CEM, Reich, K, Nestle, FO, Scher, RK, Li, S, Xu, S, Hsu, MC & Guzzo, C 2008, 'Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year', Journal of the American Academy of Dermatology, vol. 58, no. 2, pp. 224-231. https://doi.org/10.1016/j.jaad.2007.07.042

APA

Rich, P., Griffiths, C. E. M., Reich, K., Nestle, F. O., Scher, R. K., Li, S., Xu, S., Hsu, M. C., & Guzzo, C. (2008). Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology, 58(2), 224-231. https://doi.org/10.1016/j.jaad.2007.07.042

Vancouver

Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology. 2008 Feb;58(2):224-231. https://doi.org/10.1016/j.jaad.2007.07.042

Author

Rich, Phoebe ; Griffiths, Christopher E M ; Reich, Kristian ; Nestle, Frank O. ; Scher, Richard K. ; Li, Shu ; Xu, Stephen ; Hsu, Ming Chun ; Guzzo, Cynthia. / Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. In: Journal of the American Academy of Dermatology. 2008 ; Vol. 58, No. 2. pp. 224-231.

Bibtex

@article{6380b1a06713420796e469e23fc39f8a,
title = "Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year",
abstract = "Background: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. Methods: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Results: Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P <.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P <.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P <.001). Limitations: The study did not evaluate nail response beyond 1 year. Conclusions: Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement. {\textcopyright} 2008 American Academy of Dermatology, Inc.",
keywords = "Adult, therapeutic use: Antibodies, Monoclonal, Female, Humans, Male, Middle Aged, drug therapy: Nail Diseases, drug therapy: Psoriasis",
author = "Phoebe Rich and Griffiths, {Christopher E M} and Kristian Reich and Nestle, {Frank O.} and Scher, {Richard K.} and Shu Li and Stephen Xu and Hsu, {Ming Chun} and Cynthia Guzzo",
year = "2008",
month = feb,
doi = "10.1016/j.jaad.2007.07.042",
language = "English",
volume = "58",
pages = "224--231",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby, Incorporated",
number = "2",

}

RIS

TY - JOUR

T1 - Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

AU - Rich, Phoebe

AU - Griffiths, Christopher E M

AU - Reich, Kristian

AU - Nestle, Frank O.

AU - Scher, Richard K.

AU - Li, Shu

AU - Xu, Stephen

AU - Hsu, Ming Chun

AU - Guzzo, Cynthia

PY - 2008/2

Y1 - 2008/2

N2 - Background: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. Methods: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Results: Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P <.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P <.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P <.001). Limitations: The study did not evaluate nail response beyond 1 year. Conclusions: Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement. © 2008 American Academy of Dermatology, Inc.

AB - Background: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. Methods: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Results: Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P <.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P <.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P <.001). Limitations: The study did not evaluate nail response beyond 1 year. Conclusions: Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement. © 2008 American Academy of Dermatology, Inc.

KW - Adult

KW - therapeutic use: Antibodies, Monoclonal

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - drug therapy: Nail Diseases

KW - drug therapy: Psoriasis

U2 - 10.1016/j.jaad.2007.07.042

DO - 10.1016/j.jaad.2007.07.042

M3 - Article

VL - 58

SP - 224

EP - 231

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -